Pharma firm Suven Life Sciences today said the European Patent Office (EPO) has issued patent to one of its compound which is used in treating disorders like Alzheimer's, Parkinson and Schizophrenia.
The company secures product patent for one of its new chemical entity (NCE) which is used for the treatment of disorders associated with neurodegenerative diseases, valid until 2025, Suven said in a statement.
The granted claims of the patent include the class of selective compounds discovered by Suven and are useful in the treatment related to neurodegenerative disorders like Alzheimer's disease, Parkinson and Schizophrenia, it said.
With this new patent, Suven has a total of eight granted European product patents for their NCEs in central nervous system therapy.
All the eight EPO patents have been validated in the 37 member countries of Europe, including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland.
Shares of Suven Lifesciences were trading at Rs 33.80 on BSE, up 3.68 per cent from previous close.
